Noom Med review: program names change both price and what is included

Introductory and quarterly charges

The GLP-1Rx program lists $129 to start and $249 per month after the initial four-week supply, billed quarterly. Plus lists $149 to start and $299 per month afterward, also quarterly. Microdose lists $49 to start and $179 per month afterward. Those figures should not be reduced to a single Noom price; the later bill and program selection matter more than the cheapest opening headline.

Sources: Noom Med - GLP-1 Medications for Weight Loss · Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs

What the all-inclusive wording covers

The pricing page says clinical care, medication and the digital program are included for its listed compounded programs. The branded access program is different: it lists $39 to start and $129 per month afterward, charged quarterly, with medication excluded. A reader seeking Wegovy or Zepbound should therefore avoid carrying the compounded-plan inclusions into the branded access calculation.

Sources: Noom Med - GLP-1 Medications for Weight Loss · Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs

For another purchase structure, read Found and Mochi Health. These links compare the offers, not individual health outcomes.

The top quartile is not the average

The 17-pound, sixty-day headline is tied to the top quarter of 1,185 users reporting weight while prescribed compounded GLP-1 medicines; the page gives a thirteen-pound average. Its six-month 35-pound headline likewise uses the top quarter of a different 1,597-person group, with a 25-pound average. These are self-reported program figures, not randomized comparisons or individual forecasts.

Sources: Noom Med - GLP-1 Medications for Weight Loss · Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs

App engagement does not establish causation

A separate branded-program footnote describes an analysis of 14,203 members logging weight over forty weeks. Higher app engagement was associated with greater weight loss, and the page explicitly says that does not imply causation. That distinction supports judging the program’s coaching and tracking features as services rather than treating an engagement statistic as proof that the app produces a particular clinical benefit.

Sources: Noom Med - GLP-1 Medications for Weight Loss · Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs

Keep the full cost calculation and branded-versus-compounded distinction visible. Our evidence guide explains why different result types cannot be scored as one clinical ranking.

Use the page as a starting point

Public offer pages can explain a purchase without establishing everything about care. A listed medicine may be subject to clinical review, an insurer may decline coverage and an advertised shipping estimate may not describe a particular order. The practical question is whether the exact prescription, recurring bill and clinical contact are clear before commitment, rather than whether the page has the most persuasive testimonial.

Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK

Where this review ends

This review was written from official public pages available on October 1, 2026. We did not receive patient care, test medication, inspect a pharmacy or verify a completed purchase. Prices and program descriptions can change. FDA’s warning about unapproved GLP-1 products explains a regulatory distinction; it is not independent validation of this particular provider or product. Individual benefits, risks and eligibility require a qualified clinician.

Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss